STAAR Surgical Co (STAA) company profile

STAAR Surgical Company designs, manufactures, and markets implantable lenses and delivery systems for ophthalmic surgery, specializing in phakic intraocular lenses used in refractive eye care. Its principal offerings comprise the EVO family of Implantable Collamer Lenses (ICLs), which include models such as EVO, EVO+, EVO Visian, and EVO Viva, designed to correct refractive vision conditions including myopia, astigmatism, and presbyopia without removing corneal tissue. The company sells its vision correction solutions globally to ophthalmic surgeons and patients seeking alternatives to eyeglasses or contact lenses.

The company distributes its products in more than 85 countries through direct representatives and independent distributors, generating the substantial majority of its sales internationally. STAAR maintains manufacturing, administrative, or research operations across the United States, Switzerland, and Japan, including facilities in Monrovia, Aliso Viejo, Tustin, Brügg, and Nidau. Its corporate headquarters is located in Lake Forest, California.

Summary of the business section of STAAR Surgical's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of January 2, 2026, we had approximately 957 employees, of which 406 were employed outside the U.S.”